IMARA Inc.
IMARA Inc. is listed today as Enliven Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2024 | $90 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| Mar 2019 | $44 M | No. 2 | $10 to $50 million | equity | SEC | |
| Apr 2016 | $6 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
IMARA Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2024).
SEC Form D · Apr 2024
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Apr 2024
That is all the official record says: IMARA Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of IMARA Inc. are on record.
Investors#
21 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alexandria Venture Investments, LLC | Venture capital | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Arix Bioscience Holdings Ltd | Company | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Arix Bioscience PLC | Company | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Bay City Capital Fund V Co-Investment Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Bay City Capital Fund V, L.P. | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Bay City Capital LLC | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Bay City Capital Management V LLC | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Invest A/s Lundbeckfond | Person | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Lundbeck A. S. H. | Person | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Nea 14 GP, LTD | Company | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| NEA Partners 14, L.P. | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| New Enterprise Associates 14, L.P. | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| OrbiMed Capital GP VII LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Pfizer Inc | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Pfizer Ventures (US) LLC | Venture capital | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| RA Capital Healthcare Fund LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Rock Springs Capital LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Rock Springs Capital Management LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Rock Springs Capital Master Fund LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 11 investors.
Largest shareholders today
Institutions holding Enliven Therapeutics, Inc. shares, as of Sep 30, 2026.
- FMR LLC$496 M14.71%
- Orbimed Advisors LLC$311 M9.21%
- Polar Capital Holdings Plc$295 M8.73%
- BlackRock, Inc.$262 M7.76%
- Commodore Capital LP$150 M4.45%
- Vestal Point Capital, LP$148 M4.38%
- Vanguard Capital Management LLC$133 M3.93%
- Price T Rowe Associates Inc /MD/$108 M3.19%
- Fairmount Funds Management LLC$85 M2.52%
- Geode Capital Management, LLC$78 M2.32%
- State Street Corp$71 M2.10%
- Siren, L.L.C.$68 M2.00%
- Bellevue Group AG$67 M2.00%
- Adage Capital Partners GP, L.L.C.$67 M1.99%
- Pictet Asset Management Holding SA$61 M1.80%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Anish P. Patel | Executive officer | Apr 2024 |
| Benjamin P. Hohl | Executive officer | Apr 2024 |
| Helen P. Collins | Executive officer | Apr 2024 |
| Joseph P. Lyssikatos | Executive officer | Apr 2024 |
| Samuel Kintz | Executive officer | Apr 2024 |
| Christoph M. Adams | Executive officer | Mar 2019 |
| Rahul Ballal | Executive officer | Mar 2019 |
| James G. McArthur | Executive officer | Apr 2016 |
| Andrew P. Phillips | Director | Apr 2024 |
| Jake P. Bauer | Director | Apr 2024 |
| Joseph P. Lyssikatos | Director | Apr 2024 |
| Mika P. Derynck | Director | Apr 2024 |
| Rahul P. Ballal | Director | Apr 2024 |
| Richard P. Heyman | Director | Apr 2024 |
| Rishi P. Gupta | Director | Apr 2024 |
| Samuel Kintz | Director | Apr 2024 |
| Barbara G. Dalton | Director | Mar 2019 |
| Carl G. Goldfischer | Director | Mar 2019 |
| David G. Bonita | Director | Mar 2019 |
| David G. Mott | Director | Mar 2019 |
| James G. McArthur | Director | Mar 2019 |
| Mark G. Chin | Director | Mar 2019 |
| Mette Kirstine Agger | Director | Mar 2019 |
| Rahul Ballal | Director | Mar 2019 |
| Sara G. Nayeem | Director | Mar 2019 |
| Barbara Kirstine Dalton | Director | Apr 2016 |
| Christoph M. Adams | Director | Apr 2016 |
| David Kirstine Mott | Director | Apr 2016 |
| Robert M. Hopfner | Director | Apr 2016 |
| Sara Kirstine Nayeem | Director | Apr 2016 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.